Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush
Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 target price on the stock. HOWL has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target […]
Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 target price on the stock. HOWL has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target […]
